CLIN Clinigen Group Plc

TIDMCLIN

RNS Number : 0061X

Clinigen Group plc

20 November 2017

20 November 2017

Issue of Equity

Clinigen Group plc (AIM: CLIN, the "Group") announces that it has made an application for the admission to trading on AIM of 45,948 ordinary shares of 0.1 pence each in the Group (the "New Ordinary Shares"). These ordinary shares have been issued to satisfy share options vesting under The Clinigen Group All Staff Long Term Incentive Plan and The Clinigen Group All Staff JV Long Term Incentive Plan and rank pari passu with the existing shares of the Group. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur on 23 November 2017.

At admission the issued share capital of the Group will consist of 122,268,158 ordinary shares, with no shares held in treasury. The total number of voting rights in the Group will therefore be 122,268,158. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the Disclosure Guidance and Transparency Rules.

-Ends-

Contact details

 
 Clinigen Group plc                  Tel: +44 (0) 1283 
                                      495010 
 Shaun Chilton, Group Chief 
  Executive Officer 
 Martin Abell, Group Chief 
  Financial Officer 
 
 Numis Securities Limited            Tel: +44 (0) 20 
                                      7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
  James Black / Tom Ballard 
  (Corporate Broking) 
 
 RBC Capital Markets - Joint         Tel: +44 (0) 20 
  Broker                              7653 4000 
 Marcus Jackson / Elliot Thomas 
  / Jack Wood 
 
 Instinctif Partners                 Tel: +44 (0) 20 
                                      7457 2020 
 Melanie Toyne-Sewell / Alex 
  Shaw / Deborah Bell                Email: clinigen@instinctif.com 
 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.

For more information, please visit www.clinigengroup.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEFEDFLSFWSELF

(END) Dow Jones Newswires

November 20, 2017 09:45 ET (14:45 GMT)

Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024

Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024